Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seon-Kyeong | - |
dc.contributor.author | Song, Moo Kon | - |
dc.contributor.author | Chung, Joo Seop | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.date.accessioned | 2022-07-07T02:43:53Z | - |
dc.date.available | 2022-07-07T02:43:53Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2013-12 | - |
dc.identifier.issn | 0925-5710 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/142694 | - |
dc.description.abstract | As part of an effort to develop a more effective and safe treatment for relapsed or refractory non-Hodgkin’s lymphoma (NHL), we conducted a phase II study of the oxaliplatin, etoposide, and ifosfamide (IFETOx) regimen. Patients with relapsed or refractory NHL and a performance status of 0–2 were eligible. The IFETOx consisted of etoposide at 100 mg/m2 on days 1–3, oxaliplatin at 130 mg/m2 on day 2, and ifosfamide 5,000 mg/m2 on day 2, every 21 days. The primary endpoint was the overall response rate (ORR) for IFETOx regimen. A total of 23 eligible patients were enrolled. The median age was 58 years (range 19–76 years), and the male-to-female ratio was 15:8. The disease status was as follows: 15 patients had relapsed and 8 patients were refractory to treatment. The ORR for IFETOx chemotherapy was 65.2 %. In the 15 patients who responded to the protocol treatment, five underwent hematopoietic stem cell transplantation. The 2-year probability of progression-free survival and overall survival rates were 51.4 and 56.1 %, respectively. Grade 3/4 neutropenia was observed in 73.9 % of the patients. No significant renal impairment was observed. In conclusion, IFETOx chemotherapy shows a tolerable toxicity profile and efficacy as a salvage treatment regimen for relapsed or refractory NHL. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER JAPAN KK | - |
dc.title | Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma. | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Moo Kon | - |
dc.identifier.doi | 10.1007/s12185-013-1440-7 | - |
dc.identifier.scopusid | 2-s2.0-84892907969 | - |
dc.identifier.wosid | 000327242100007 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF HEMATOLOGY, v.98, no.5, pp.543 - 548 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF HEMATOLOGY | - |
dc.citation.title | INTERNATIONAL JOURNAL OF HEMATOLOGY | - |
dc.citation.volume | 98 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 543 | - |
dc.citation.endPage | 548 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordAuthor | Etoposide | - |
dc.subject.keywordAuthor | Ifosfamide | - |
dc.subject.keywordAuthor | Non-hodgkin&apos | - |
dc.subject.keywordAuthor | s lymphoma | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
dc.subject.keywordAuthor | Relapse | - |
dc.identifier.url | https://pubmed.ncbi.nlm.nih.gov/24068657/ | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.